These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 9797884)

  • 1. ACE inhibitors in acute myocardial infarction.
    Murdoch DR; McMurray JJ
    Hosp Med; 1998 Feb; 59(2):111-5. PubMed ID: 9797884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence.
    Simpson E; Beck C; Richard H; Eisenberg MJ; Pilote L
    Am Heart J; 2003 Mar; 145(3):438-44. PubMed ID: 12660666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
    Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 6. [Multi-drug management after myocardial infarct].
    Kritz H; Sinzinger H
    Wien Klin Wochenschr; 1997; 109 Suppl 2():17-24. PubMed ID: 9340918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R; McMurray JJ
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Magnesium sulfate in acute myocardial infarction].
    Balli E; Giomi A; Del Citerna F
    G Ital Cardiol; 1995 Nov; 25(11):1425-32. PubMed ID: 8682239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibition in myocardial infarction--Part 2: Clinical issues and controversies.
    Huckell VF; Bernstein V; Crowell R; Dagenais GR; Higginson LA; Isserow S; Laramée P; Liu P; McCans JL; Orchard RC; Prewitt R; Quinn BP; Samson M; Turazza F; Warnica JW; Wielgosz A
    Can J Cardiol; 1997 Feb; 13(2):173-82. PubMed ID: 9070169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction.
    Wienbergen H; Zeymer U; Gitt AK; Juenger C; Schiele R; Heer T; Towae F; Senges J;
    Am J Cardiol; 2007 May; 99(9):1208-11. PubMed ID: 17478143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening?
    Ho SF; O'Mahony MS; Steward JA; Burr ML; Buchalter M
    Age Ageing; 2004 Sep; 33(5):488-92. PubMed ID: 15271642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitor and/or angiotensin receptor antagonist for the postmyocardial infarction patient.
    Scott RL
    Cardiol Clin; 2008 Feb; 26(1):73-7, vii. PubMed ID: 18312907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pragmatic approach to the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction.
    Vantrimpont P; Rouleau JL
    Can J Cardiol; 1996 Oct; 12(10):924-9. PubMed ID: 9191482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management after myocardial infarction: an evidence-based perspective.
    Sharpe N
    Br J Clin Pract Suppl; 1996 Jul; 84():25-30. PubMed ID: 8994999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between mortality due to acute myocardial infarction and adherence to clinical guidelines].
    Coma-Canella I
    Rev Esp Cardiol; 2006 Mar; 59(3):189-92. PubMed ID: 16712740
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanistic and clinical rationales for using beta-blockers in heart failure.
    Bristow MR
    J Card Fail; 2000 Jun; 6(2 Suppl 1):8-14. PubMed ID: 10908093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.